论文部分内容阅读
目的:观察分析一性次球囊宫颈扩张器在足月待产孕妇中临床应用的效果及如何安全应用。方法:回顾性分析2016年1月至2017年1月在陕西中医药大学第二附属医院妇产综合科的足月待产、有计划阴道分娩的孕妇230例为研究组,给予放置一次性球囊宫颈扩张器;选取同期具有阴道分娩条件的孕妇230例为观察组,给予宫颈后穹窿放置米索前列素醇片25ug,观察分析两组孕妇的规律宫缩的时间,总产程,分娩方式,阴道分娩率,产后2小时出血量,新生儿Apgar评分等情况。结果:放置一次性球囊宫颈扩张器的孕妇规律宫缩发动时间明显早于放置米索前列素醇片的孕妇,总产程明显缩短,阴道分娩率较高(90.86%>80.81%),产时产后2小时出血量及新生儿Apgar评分与对照组无明显差异性,无统计学意义(P>0.05)。结论:与传统的阴道放置米索前列素醇片分娩相比,一次性球囊宫颈扩张器在促进宫颈成熟、调动规律宫缩及提高阴道分娩率占据着明显的优势,而且操作简单,成本较剖宫产低。这将会是缓解我国高剖宫产率的现状,值得在临床推广应用。
OBJECTIVE: To observe the clinical effect and safety of one-stage secondary balloon dilator in term pregnant women. Methods: A retrospective analysis of January 2016 to January 2017 in the Department of Obstetrics and Gynecology, Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, full-term waiting for delivery, pregnant women scheduled vaginal delivery of 230 cases for the study group, given disposable balloons Cervical dilator; select the same period of vaginal delivery conditions, 230 pregnant women as the observation group, given to the posterior fornix placed misoprostol tablets 25ug, observation and analysis of the two groups of pregnant women with regular contractions time, total labor, delivery mode, the vagina Childbirth rate, 2-hour postpartum bleeding, Apgar score and so on. Results: The contractile activity of pregnant women with disposable balloon dilator was significantly earlier than that of pregnant women with misoprostol tablets. The total labor was significantly shortened and the rate of vaginal delivery was higher (90.86%> 80.81%). There was no significant difference between the 2-hour postpartum hemorrhage volume and neonatal Apgar score and the control group (P> 0.05). Conclusion: Compared with the traditional delivery of misoprostol in vaginal delivery, the disposable balloon dilator occupies a distinct advantage in promoting cervical ripening, regular contractions and vaginal delivery, and is simple in operation and cost-effective Cesarean section low. This will be to alleviate the status of high cesarean section rate in China, it is worth in the clinical application.